Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Receivables (2019 - 2022)

4D Molecular Therapeutics (FDMT) has disclosed Receivables for 4 consecutive years, with $700000.0 as the latest value for Q4 2022.

  • On a quarterly basis, Receivables fell 6.29% to $700000.0 in Q4 2022 year-over-year; TTM through Dec 2022 was $700000.0, a 6.29% decrease, with the full-year FY2022 number at $700000.0, down 6.29% from a year prior.
  • Receivables was $700000.0 for Q4 2022 at 4D Molecular Therapeutics, down from $747000.0 in the prior quarter.
  • In the past five years, Receivables ranged from a high of $1.5 million in Q4 2020 to a low of $561000.0 in Q1 2021.
  • A 4-year average of $902000.0 and a median of $769000.0 in 2021 define the central range for Receivables.
  • Peak YoY movement for Receivables: skyrocketed 31.85% in 2020, then crashed 49.73% in 2021.
  • 4D Molecular Therapeutics' Receivables stood at $1.1 million in 2019, then soared by 31.85% to $1.5 million in 2020, then tumbled by 49.73% to $747000.0 in 2021, then decreased by 6.29% to $700000.0 in 2022.
  • Per Business Quant, the three most recent readings for FDMT's Receivables are $700000.0 (Q4 2022), $747000.0 (Q4 2021), and $791000.0 (Q3 2021).